The Indian Polycap Study (TIPS) - Authors' reply

The Lancet

Volumn 374, Issue 9692, 2009, Pages 782-

  Yusuf, Salim ^a   Pais, Prem ^b   Xavier, Denis ^b  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; LETTER; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION;

EID: 69449096505     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61587-7     Document Type: Letter

References (5)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
2. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
3. Beta-Block Heart Attack Study Group. The beta-blocker heart attack trial. JAMA 246 (1981) 2073-2074
4. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
5. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788